Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Pharmacokinetics of 14C-SEP-380135 in Healthy Male Adults
NCT07455084Phase 1Not yet recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SEP-380135 in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Total Radioactivity Amount Excreted in Urine, Total Radioactivity Amount Excreted in Feces and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SEP-380135
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07455084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455084.